O Shaughnessy Asset Management LLC Buys 20,950 Shares of Pfizer Inc. (NYSE:PFE)

O Shaughnessy Asset Management LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 7.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 317,495 shares of the biopharmaceutical company’s stock after acquiring an additional 20,950 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Pfizer were worth $8,810,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of PFE. Advisor OS LLC raised its stake in Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after purchasing an additional 365 shares during the period. Safeguard Investment Advisory Group LLC raised its position in shares of Pfizer by 3.9% during the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 371 shares during the last quarter. Lantz Financial LLC raised its position in shares of Pfizer by 1.3% during the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after buying an additional 381 shares during the last quarter. Wellington Shields Capital Management LLC lifted its holdings in shares of Pfizer by 1.3% in the first quarter. Wellington Shields Capital Management LLC now owns 30,750 shares of the biopharmaceutical company’s stock worth $853,000 after buying an additional 385 shares in the last quarter. Finally, King Wealth Management Group boosted its position in shares of Pfizer by 2.4% during the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock worth $480,000 after acquiring an additional 388 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 1.6 %

PFE traded up $0.48 during trading on Wednesday, reaching $29.98. The company had a trading volume of 27,144,018 shares, compared to its average volume of 39,684,977. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The business has a 50 day simple moving average of $28.45 and a 200-day simple moving average of $27.73. The stock has a market cap of $169.88 billion, a P/E ratio of -497.92, a PEG ratio of 1.16 and a beta of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.72.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the business earned $1.23 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.60%. Pfizer’s dividend payout ratio is -2,799.53%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PFE shares. Barclays lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 10th. Morgan Stanley boosted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, July 10th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $34.50.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.